{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:18:54Z","timestamp":1792815534174,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"foundation for the national institutes of health","doi-asserted-by":"publisher","award":["#5T32 DA007233-35"],"award-info":[{"award-number":["#5T32 DA007233-35"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"foundation for the national institutes of health","doi-asserted-by":"publisher","award":["R01DA041298"],"award-info":[{"award-number":["R01DA041298"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"foundation for the national institutes of health","doi-asserted-by":"publisher","award":["R01DA041501"],"award-info":[{"award-number":["R01DA041501"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"name":"nyu center for drug use and hiv\/hcv research","award":["NOH P30 DA011041"],"award-info":[{"award-number":["NOH P30 DA011041"]}],"id":[{"id":"https:\/\/ror.org\/0182vay76","id-type":"ROR","asserted-by":"crossref"}]},{"name":"nyu center for opioid epidemiology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Methadone Maintenance Treatment (MMT) is widely recognized as one of the most effective ways of reducing risk of overdose, arrest, and transmission of blood-borne viruses like HIV and HCV among people that use opioids. Yet, MMT\u2019s use of restrictive take-home dose policies that force most patients to attend their clinic on a daily, or near-daily, basis may be unpopular with many patients and lead to low rates of treatment uptake and retention. In response, this article examines how clinics\u2019 take-home dosing policies have affected patients\u2019 experiences of treatment and lives in general.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This article is based on semi-structured, qualitative interviews with a variety of stakeholders in MMT. Interviews explored: reasons for engaging with, or not engaging with MMT; how MMT is conceptualized by patients and treatment providers (e.g., as harm reduction or route to abstinence and\/or recovery); experiences with MMT; perception of barriers to MMT (e.g., organizational\/regulatory, social) and how MMT might be improved to support peoples\u2019 substance use treatment needs and goals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nearly all of the patients with past or present MMT use were highly critical of the limited access to take-home doses and consequent need for daily or near daily clinic attendance. Participants described how the use of restrictive take-home dose policies negatively impacted their ability to meet day-to-day responsibilities and also cited the need for daily attendance as a reason for quitting or avoiding OAT. Responses also demonstrate how such policies contribute to an environment of cruelty and stigma within many clinics that exposes this already-stigmatized population to additional trauma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Take-home dose policies in MMT are not working for a substantial number of patients and are reasonably seen by participants as degrading and dehumanizing. Revision of MMT regulations and policies regarding take home doses are essential to improve patient satisfaction and the quality and effectiveness of MMT as a key evidence-based treatment and harm reduction strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-021-00535-y","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T08:04:47Z","timestamp":1628928287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":178,"title":["\u201cIt\u2019s like \u2018liquid handcuffs\u201d: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3304-3237","authenticated-orcid":false,"given":"David","family":"Frank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Mateu-Gelabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Perlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan M.","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Curran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honoria","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"key":"535_CR1","doi-asserted-by":"crossref","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. bmj. 2017;357.","DOI":"10.1136\/bmj.j1550"},{"key":"535_CR2","unstructured":"Karki P, Shrestha R, Huedo-Medina TB, Copenhaver M. The impact of methadone maintenance treatment on HIV risk behaviors among high-risk injection drug users: a systematic review. Evid Based Med Public Health. 2016;2."},{"key":"535_CR3","doi-asserted-by":"crossref","unstructured":"Schwartz RP, Gryczynski J, O\u2019grady KE, Sharfstein JM, Warren G, Olsen Y, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995\u20132009. Am J Public Health. 2013;103(5):917\u201322.","DOI":"10.2105\/AJPH.2012.301049"},{"issue":"1\u20132","key":"535_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2009.05.021","volume":"105","author":"L Degenhardt","year":"2009","unstructured":"Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009;105(1\u20132):9\u201315.","journal-title":"Drug Alcohol Depend"},{"key":"535_CR5","unstructured":"Union US. The methadone manifesto. Urban Survivors Union; 2021."},{"key":"535_CR6","unstructured":"Redmond H. The methadone manifesto: a powerful blow against the clinic system. Filter Magazine. 2021."},{"key":"535_CR7","unstructured":"Substance Abuse and Mental Health Services Administration CfBHSaQ, Rockville, MD. Treatment Episode Data Set (TEDS): 2017. Admissions to and Discharges from Publicly-Funded Substance Use Treatment. 2019."},{"issue":"14","key":"535_CR8","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1001\/jama.2015.10345","volume":"314","author":"B Saloner","year":"2015","unstructured":"Saloner B, Karthikeyan S. Changes in substance abuse treatment use among individuals with opioid use disorders in the United States, 2004\u20132013. JAMA. 2015;314(14):1515\u20137.","journal-title":"JAMA"},{"issue":"2","key":"535_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/10826084.2017.1310247","volume":"53","author":"D Frank","year":"2018","unstructured":"Frank D. \u201cI was not sick and I didn\u2019t need to recover\u201d: Methadone Maintenance Treatment (MMT) as a refuge from criminalization. Subst Use Misuse. 2018;53(2):311\u201322.","journal-title":"Subst Use Misuse"},{"issue":"2","key":"535_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/ADM.0b013e3181e6ad48","volume":"5","author":"E Peles","year":"2011","unstructured":"Peles E, Schreiber S, Sason A, Adelson M. Earning, \u201ctake-home\u201d privileges and long-term outcome in a methadone maintenance treatment program. J Addict Med. 2011;5(2):92\u20138.","journal-title":"J Addict Med"},{"key":"535_CR11","doi-asserted-by":"crossref","unstructured":"Figgatt MC, Salazar Z, Day E, Vincent L, Dasgupta N. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. J Substance Abuse Treat. 2021;123:108276.","DOI":"10.1016\/j.jsat.2021.108276"},{"key":"535_CR12","volume-title":"Engaging people with lived experience for better health outcomes: collaboration with mental health and addiction service users in research, policy, and treatment","author":"R Cheng","year":"2009","unstructured":"Cheng R, Smith C. Engaging people with lived experience for better health outcomes: collaboration with mental health and addiction service users in research, policy, and treatment. Toronto: Ontario Ministry of Health and Long-Term Care; 2009."},{"key":"535_CR13","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3389\/fpsyg.2019.01052","volume":"10","author":"D Eddie","year":"2019","unstructured":"Eddie D, Hoffman L, Vilsaint C, Abry A, Bergman B, Hoeppner B, et al. Lived experience in new models of care for substance use disorder: a systematic review of peer recovery support services and recovery coaching. Front Psychol. 2019;10:1052.","journal-title":"Front Psychol"},{"key":"535_CR14","unstructured":"Substance Abuse and Mental Health Services Administration CfBHSaQ, Rockville, MD. Federal Guidelines for Opioid Treatment Programs. 2015."},{"issue":"2","key":"535_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5617\/jea.6737","volume":"3","author":"D Frank","year":"2019","unstructured":"Frank D. We\u2019re gonna be addressing your pepsi use. J Extreme Anthropol. 2019;3(2):1\u201320.","journal-title":"J Extreme Anthropol"},{"issue":"3","key":"535_CR16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/ADM.0b013e3182584772","volume":"6","author":"AY Walley","year":"2012","unstructured":"Walley AY, Cheng DM, Pierce CE, Chen C, Filippell T, Samet JH, et al. Methadone dose, take home status and hospital admission among Methadone Maintenance patients. J Addict Med. 2012;6(3):186.","journal-title":"J Addict Med"},{"key":"535_CR17","doi-asserted-by":"crossref","unstructured":"Hatch-Maillette MA, Peavy KM, Tsui JI, Banta-Green CJ, Woolworth S, Grekin P. Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives. J Substance Abuse Treat. 2021;124:108223.","DOI":"10.1016\/j.jsat.2020.108223"},{"issue":"1","key":"535_CR18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0376-8716(96)01240-9","volume":"41","author":"PP Pani","year":"1996","unstructured":"Pani PP, Pirastu R, Ricci A, Gessa GL. Prohibition of take-home dosages: negative consequences on methadone maintenance treatment. Drug Alcohol Depend. 1996;41(1):81\u20134.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"535_CR19","first-page":"33","volume":"2","author":"PP Pani","year":"2000","unstructured":"Pani PP, Pirastu R. Take-home and compliance with methadone maintenance treatment. Heroin Addict Relat Clin Probl. 2000;2(1):33\u20138.","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"535_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2018.07.006","volume":"93","author":"S Amiri","year":"2018","unstructured":"Amiri S, Lutz R, Soc\u00edas ME, McDonell MG, Roll JM, Amram O. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. J Subst Abuse Treat. 2018;93:26\u201330.","journal-title":"J Subst Abuse Treat"},{"key":"535_CR21","unstructured":"Substance Abuse and Mental Health Services Administration CfBHSaQ, Rockville, MD. Opioid Treatment Program (OTP) guidance. In: Health Do, editor. 2020."},{"key":"535_CR22","doi-asserted-by":"crossref","unstructured":"Brothers S, Viera A, Heimer R. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19. J Substance Abuse Treat. 2021:108449.","DOI":"10.1016\/j.jsat.2021.108449"},{"issue":"9","key":"535_CR23","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1007\/s10461-020-02887-1","volume":"24","author":"KM Peavy","year":"2020","unstructured":"Peavy KM, Darnton J, Grekin P, Russo M, Green CJB, Merrill JO, et al. Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program. AIDS Behav. 2020;24(9):2469\u201372.","journal-title":"AIDS Behav"},{"key":"535_CR24","doi-asserted-by":"crossref","unstructured":"Samuels EA, Clark SA, Wunsch C, Keeler LAJ, Reddy N, Vanjani R, et al. Innovation during COVID-19: improving addiction treatment access. J Addict Med. 2020.","DOI":"10.1097\/ADM.0000000000000685"},{"key":"535_CR25","doi-asserted-by":"crossref","unstructured":"Krawczyk N, Fingerhood MI, Agus D. Lessons from COVID 19: are we finally ready to make opioid treatment accessible? J Substance Abuse Treat. 2020;117.","DOI":"10.1016\/j.jsat.2020.108074"},{"issue":"1","key":"535_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11648\/j.ajtas.20160501.11","volume":"5","author":"I Etikan","year":"2016","unstructured":"Etikan I, Musa SA, Alkassim RS. Comparison of convenience sampling and purposive sampling. Am J Theor Appl Stat. 2016;5(1):1\u20134.","journal-title":"Am J Theor Appl Stat"},{"issue":"5","key":"535_CR27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.colegn.2018.01.002","volume":"25","author":"AE Butler","year":"2018","unstructured":"Butler AE, Copnell B, Hall H. The development of theoretical sampling in practice. Collegian. 2018;25(5):561\u20136.","journal-title":"Collegian"},{"key":"535_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4135\/9781849208574.n4","volume":"703","author":"GR Gibbs","year":"2007","unstructured":"Gibbs GR. Thematic coding and categorizing. Analyzing Qual Data. 2007;703:38\u201356.","journal-title":"Analyzing Qual Data"},{"key":"535_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fsoc.2021.619677","volume":"6","author":"D Frank","year":"2021","unstructured":"Frank D, Walters SM. \u201cI\u2019m going to stop myself before someone stops me\u201d: complicating narratives of volitional substance use treatment. Front Sociol. 2021;6:6.","journal-title":"Front Sociol"},{"issue":"3","key":"535_CR30","first-page":"1","volume":"30","author":"CB Fisher","year":"2008","unstructured":"Fisher CB, Oransky M, Mahadevan M, Singer M, Mirhej G, Hodge D. Marginalized populations and drug addiction research: realism, mistrust, and misconception. IRB. 2008;30(3):1.","journal-title":"IRB"},{"issue":"2","key":"535_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/08964289.2019.1619511","volume":"45","author":"J Jaiswal","year":"2019","unstructured":"Jaiswal J, Halkitis PN. Towards a more inclusive and dynamic understanding of medical mistrust informed by science. Behav Med. 2019;45(2):79\u201385.","journal-title":"Behav Med"},{"issue":"1","key":"535_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12910-016-0108-2","volume":"17","author":"R Souleymanov","year":"2016","unstructured":"Souleymanov R, Kuzmanovi\u0107 D, Marshall Z, Scheim AI, Mikiki M, Worthington C, et al. The ethics of community-based research with people who use drugs: results of a scoping review. BMC Med Ethics. 2016;17(1):1\u201313.","journal-title":"BMC Med Ethics"},{"key":"535_CR33","unstructured":"Naples NA. Feminism and method: Ethnography, discourse analysis, and activist research: Psychology Press; 2003."},{"issue":"5","key":"535_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1037\/cou0000203","volume":"64","author":"B Moradi","year":"2017","unstructured":"Moradi B, Grzanka PR. Using intersectionality responsibly: Toward critical epistemology, structural analysis, and social justice activism. J Couns Psychol. 2017;64(5):500.","journal-title":"J Couns Psychol"},{"key":"535_CR35","unstructured":"Graham LJ, editor Discourse analysis and the critical use of Foucault. The Australian Association of Research in Education Annual Conference; 2005."},{"issue":"1","key":"535_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.soc.22.1.29","volume":"22","author":"ML DeVault","year":"1996","unstructured":"DeVault ML. Talking back to sociology: distinctive contributions of feminist methodology. Ann Rev Sociol. 1996;22(1):29\u201350.","journal-title":"Ann Rev Sociol"},{"key":"535_CR37","doi-asserted-by":"crossref","unstructured":"Agamben G. I. HOMO SACER: Sovereign power and bare life. Stanford University Press; 2020.","DOI":"10.1515\/9780804764025"},{"key":"535_CR38","unstructured":"Agamben G. State of exception. Nova srpska politi\u010dka misao. 2005;12(01+ 04):135\u201345."},{"issue":"2","key":"535_CR39","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1023\/A:1005574918294","volume":"24","author":"P Bourgois","year":"2000","unstructured":"Bourgois P. Disciplining addictions: the bio-politics of methadone and heroin in the United States. Cult Med Psychiatry. 2000;24(2):165\u201395.","journal-title":"Cult Med Psychiatry"},{"issue":"5","key":"535_CR40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.drugpo.2008.10.005","volume":"20","author":"H Keane","year":"2009","unstructured":"Keane H. Foucault on methadone: beyond biopower. Int J Drug Policy. 2009;20(5):450\u20132.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"535_CR41","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1146\/annurev.so.18.080192.001233","volume":"18","author":"P Conrad","year":"1992","unstructured":"Conrad P. Medicalization and social control. Ann Rev Sociol. 1992;18(1):209\u201332.","journal-title":"Ann Rev Sociol"},{"issue":"1","key":"535_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2307\/799624","volume":"23","author":"P Conrad","year":"1975","unstructured":"Conrad P. The discovery of hyperkinesis: notes on the medicalization of deviant behavior. Soc Probl. 1975;23(1):12\u201321.","journal-title":"Soc Probl"},{"key":"535_CR43","doi-asserted-by":"publisher","first-page":"102844","DOI":"10.1016\/j.drugpo.2020.102844","volume":"83","author":"D Frank","year":"2020","unstructured":"Frank D. Methadone maintenance treatment is swapping one drug for another, and that\u2019s why it works: Towards a treatment-based critique of the war on drugs. International Journal of Drug Policy. 2020;83:102844.","journal-title":"International Journal of Drug Policy."},{"key":"535_CR44","unstructured":"Substance Abuse and Mental Health Services Administration CfBHSaQ, Rockville, MD. Treatment Episode Data Set. 2014."},{"issue":"3","key":"535_CR45","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1521-0391.2012.12004.x","volume":"22","author":"J Gryczynski","year":"2013","unstructured":"Gryczynski J, Jaffe JH, Schwartz RP, Du\u0161ek KA, Gugsa N, Monroe CL, et al. Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addict. 2013;22(3):285\u201391.","journal-title":"Am J Addict"},{"issue":"3","key":"535_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3109\/16066359808993303","volume":"6","author":"AJ Saxon","year":"1998","unstructured":"Saxon AJ, Calsyn DA, Wells EA, Stanton VV. The use of urine toxicology to enhance patient control of take-home doses in methadone maintenance: effects on reducing illicit drug use. Addict Res. 1998;6(3):203\u201314.","journal-title":"Addict Res"},{"issue":"6","key":"535_CR47","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.drugpo.2012.10.003","volume":"24","author":"M Harris","year":"2013","unstructured":"Harris M, Rhodes T. Methadone diversion as a protective strategy: the harm reduction potential of \u2018generous constraints.\u2019 Int J Drug Policy. 2013;24(6):e43\u201350.","journal-title":"Int J Drug Policy"},{"issue":"3","key":"535_CR48","first-page":"293","volume":"293","author":"TJ Cicero","year":"2005","unstructured":"Cicero TJ, Inciardi JA. Diversion and abuse of methadone prescribed for pain management. JAMA. 2005;293(3):293\u20138.","journal-title":"JAMA"},{"key":"535_CR49","unstructured":"Rettig RA, Yarmolinsky A. Methadone diversion control. Federal Regulation of Methadone Treatment. National Academies Press (US); 1995."},{"issue":"26","key":"535_CR50","doi-asserted-by":"publisher","first-page":"667","DOI":"10.15585\/mmwr.mm6526a2","volume":"65","author":"CM Jones","year":"2016","unstructured":"Jones CM, Baldwin GT, Manocchio T, White JO, Mack KA. Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths\u2014United States, 2002\u20132014. Morb Mortal Wkly Rep. 2016;65(26):667\u201371.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"6","key":"535_CR51","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1080\/10826084.2018.1555597","volume":"54","author":"CA Latkin","year":"2019","unstructured":"Latkin CA, Dayton L, Davey-Rothwell MA, Tobin KE. Fentanyl and drug overdose: perceptions of fentanyl risk, overdose risk behaviors, and opportunities for intervention among people who use opioids in Baltimore, USA. Subst Use Misuse. 2019;54(6):998\u20131006.","journal-title":"Subst Use Misuse"},{"issue":"43","key":"535_CR52","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.15585\/mmwr.mm6643e1","volume":"66","author":"JK O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths involving fentanyl, fentanyl analogs, and U-47700\u201410 states, July\u2013December 2016. MMWR Morb Mortal Wkly Rep. 2017;66(43):1197.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"34","key":"535_CR53","doi-asserted-by":"publisher","first-page":"904","DOI":"10.15585\/mmwr.mm6634a3","volume":"66","author":"R Daniulaityte","year":"2017","unstructured":"Daniulaityte R, Juhascik MP, Strayer KE, Sizemore IE, Harshbarger KE, Antonides HM, et al. Overdose deaths related to fentanyl and its analogs\u2014Ohio, January\u2013February 2017. MMWR Morb Mortal Wkly Rep. 2017;66(34):904.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"535_CR54","doi-asserted-by":"crossref","unstructured":"Blum K, Han D, Femino J, Smith DE, Saunders S, Simpatico T, et al. Systematic evaluation of \u201ccompliance\u201d to prescribed treatment medications and \u201cabstinence\u201d from psychoactive drug abuse in chemical dependence programs: data from the comprehensive analysis of reported drugs. PLoS ONE. 2014;9(9):e104275.","DOI":"10.1371\/journal.pone.0104275"},{"issue":"5\u20136","key":"535_CR55","first-page":"347","volume":"67","author":"H Joseph","year":"2000","unstructured":"Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med New York. 2000;67(5\u20136):347\u201364.","journal-title":"Mt Sinai J Med New York"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-021-00535-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-021-00535-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T06:10:49Z","timestamp":1673071849000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-021-00535-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1186\/s12954-021-00535-y","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,14]]},"assertion":[{"value":"29 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by The New York University Institutional Review Board. All participants provided informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}